Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

The gold standard is the Abnormal Involuntary Movement Scale, or the AIMS, although generally we kind of want to avoid premature TD labels, and we want to ensure that there's a causal link, in this ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

Earlier this month, in the first week of May, many mental health advocates, psychiatrists, and patients around the country observed Tardive Dyskinesia (TD) Awareness Week. Tardive dyskinesia is a ...

The double-blind, placebo-controlled Phase II trial is enrolling approximately 100 adult participants with tardive dyskinesia ...

Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics. Characterized ...

Some studies suggest vitamin E may help ease symptoms of tardive dyskinesia — but how strong is the evidence, and what does it really tell us? Note: The U.S. Food and Drug Administration (FDA) does ...

This story also appeared on Everyday Heath's network site BP Hope. The U.S. Food and Drug Administration (FDA) has approved a new sprinkle formulation of valbenazine (Ingrezza) for individuals with ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...

Study reveals over half of long-term care residents with tardive dyskinesia do not receive standard treatment, highlighting care gaps. Less than half of patients diagnosed with tardive dyskinesia in ...